Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Merck & Co Inc advances development program for investigational Alzheimer’s Disease Therapy, MK-8931


Tuesday, 10 Dec 2013 07:00am EST 

Merck & Co Inc:Says it provided an update on the development program for MK-8931, a investigational oral β-amyloid precursor protein site-cleaving enzyme (BACE) inhibitor.Says the data monitoring committee (DMC) for the Phase II/III EPOCH study in patients with mild to moderate Alzheimer's disease recently completed its planned interim safety analysis and recommended that the trial continue to recruit patients, with no changes to the protocol.Says the DMC recommendation was made following a planned analysis of interim safety data that included a safety cohort of 200 patients treated with MK-8931 for at least three months.Says based upon the DMC`s recommendations, Merck will continue enrollment of the EPOCH study.Says in addition, it will initiate dosing in a new Phase III study (APECS study) evaluating MK-8931 in patients with amnestic mild cognitive impairment due to Alzheimer's disease, also known as prodromal Alzheimer`s disease. 

Company Quote

57.88
-0.46 -0.79%
4 Mar 2015